Recombinant Human TREM-1 His-tag Protein, CF

When Recombinant Human PGLYRP1/PGRP-S Protein (Catalog # 2590-PGB) is coated at 2 μg/mL (100 μL/well), the concentration of Recombinant Human TREM-1 His-tag (Catalog # 10337-TR) that produces 50% of the optimal binding response is found to be approximately 50‑300 ng/mL.

2 μg/lane of Recombinant Human TREM-1 His-tag (Catalog # 10337-TR) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 30-45 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TREM-1 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human PGLYRP1/PGRP-S Protein (Catalog # 2590-PGB) is coated at 2 μg/mL (100 μL/well), the concentration of Recombinant Human TREM-1 His-tag (Catalog # 10337-TR) that produces 50% of the optimal binding response is found to be approximately 50-300 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human TREM-1 protein
  Ala21-Arg200, with a C-terminal 6-His tag
• Accession #: Q9NP99.1
• N-terminal Sequence: Ala21
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity2
• Theoretical MW: 21 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 30-45 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TREM-1 His-tag Protein, CF

• CD354 antigen
• CD354
• TREM1
• TREM-1
• TREM-1Triggering receptor expressed on monocytes 1
• triggering receptor expressed on myeloid cells 1
• triggering-receptor TREM1

Background

TREM-1 (Triggering Receptor Expressed on Myeloid cells), also known as CD354, along with TREM-2, and rodent specific TREM-3, comprise a group of Ig superfamily proteins regulating the activation and differentiation of myeloid cells. Human TREM-1 is type I transmembrane protein containing a single Ig-like domain in the extracellular domain (ECD), a transmembrane region and a short cytoplasmic tail. The mature ECD of human TREM-1 shares 45% identity with mouse TREM-1. Several other TREM family members have been reported that are structurally similar but share less than 30% amino acid identity. TREM-1, expressed on monocytes and neutrophils, associates with the adapter protein, DAP12, to deliver an activating signal to elicit and amplify the innate inflammatory response triggered by bacteria (1, 2). A few potential TREM-1 ligands have been identified, including HMGB1 and PGLYRP1 (1-2). HMGB1 (high mobility group Box 1), a ubiquitous nuclear protein, is secreted by myeloid cells during inflammation and has been suggested as an additional TREM-1 ligand (1). However, HMGB1 alone has been found unable to trigger TREM-1 activation and may require co-activating molecules (1). PGLYRP1 (peptidoglycan recognition receptor 1), mainly found in granulocytes, binds to peptidoglycan and cell wall components such as LPS, and has been identified as another potential TREM-1 ligand (1, 2). PGLYRP1, when complexed with PGN, is able to activate TREM-1 and enhance cytokine production in human neutrophils and macrophages (2).

1. Tammaro, et al. (2017) Pharmacology & Therapeutics. 177:81.
2. Read, et al. (2015) J Immunol. 194:1417.

Bioinformatics

• Uniprot:
  • Q9NP99.1()